Abstract
In the latest volley in the USA's gene-patenting wars, the US Court of Appeals ruled that genes could be patented, overturning a lower court's decision from 2010. The new ruling upholds Myriad Genetics' patent rights on the breast and ovarian cancer-risk genes BRCA1 and BRCA2, and protects its BRACAnalysis test. However, the court also ruled that Myriad Genetics could not patent its gene mutation analysis method. “Our patent position is as strong today as when the American Civil Liberties Union (ACLU) brought the suit”, Myriad spokesperson Rebecca Chambers commented about the July 29, 2011, decision. The lawsuit also pertains to 4000 other patented genes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
